Who are Bromhexine and Spironolactone's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/bromhexine-and-spironolactone.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Bromhexine and Spironolactone — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Bromhexine and Spironolactone (Bromhexine and Spironolactone) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Mucolytic agent combined with potassium-sparing diuretic/aldosterone antagonist. Area: Respiratory and Cardiovascular.

phase 3 Mucolytic agent combined with potassium-sparing diuretic/aldosterone antagonist Mucopolysaccharide degradation (bromhexine); mineralocorticoid receptor (spironolactone) Respiratory and Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Bromhexine and Spironolactone (Bromhexine and Spironolactone) — Lomonosov Moscow State University Medical Research and Educational Center. Bromhexine acts as a mucolytic agent to thin respiratory secretions while spironolactone is a potassium-sparing diuretic and aldosterone antagonist.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Bromhexine and Spironolactone TARGET	Bromhexine and Spironolactone	Lomonosov Moscow State University Medical Research and Educational Center	phase 3	Mucolytic agent combined with potassium-sparing diuretic/aldosterone antagonist	Mucopolysaccharide degradation (bromhexine); mineralocorticoid receptor (spironolactone)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Mucolytic agent combined with potassium-sparing diuretic/aldosterone antagonist class)

Lomonosov Moscow State University Medical Research and Educational Center · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Bromhexine and Spironolactone — Competitive Intelligence Brief. https://druglandscape.com/ci/bromhexine-and-spironolactone. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab